Welcome to our dedicated page for Enzo Biochem SEC filings (Ticker: ENZB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Enzo Biochem, Inc. (ENZB), a life sciences company whose primary business is conducted through Enzo Life Sciences. While no specific filings are listed in the provided data, Enzo has indicated that details of its Agreement and Plan of Merger with Battery Ventures will be described in a Current Report on Form 8-K filed with the SEC.
Key filing types for ENZB may include annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe a company’s business, risk factors, and financial condition. In its own communications, Enzo refers to risk factors discussed in its Annual Report on Form 10-K for a stated fiscal year, underscoring the importance of that document for understanding the company’s operations, proprietary technologies, and related risks.
For the announced all-cash merger with Battery Ventures, the company has indicated that a Form 8-K will provide further transaction details. Such a filing can include information about the merger agreement, consideration to be paid, closing conditions, and related support agreements. Investors interested in the transition of ENZB from a publicly traded company on OTCQX to a privately held entity can review these filings to understand the structure and terms of the transaction.
On a platform that aggregates SEC data, users can typically see new ENZB filings as they appear on EDGAR, along with AI-powered summaries that explain the contents of lengthy documents such as 10-Ks, 10-Qs, and 8-Ks. These tools can help clarify how Enzo Biochem describes its labeling and detection technologies, product portfolio, licensing activities, and the implications of its pending merger with Battery Ventures.
Enzo Biochem (ENZB): Schedule 13G/A filed by Beryl Capital entities shows no current stake. Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin reported 0 shares and 0% beneficial ownership of Enzo Biochem common stock (CUSIP 294100102) as of 09/30/2025.
The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Item 5 indicates ownership of five percent or less of the class. All voting and dispositive powers are listed as 0.
FAQ
What is the current stock price of Enzo Biochem (ENZB)?
What is the market cap of Enzo Biochem (ENZB)?
